Zurn Elkay Water Solutions Corporation

A valuation premium is justified given improving end-market tailwinds, visible acceleration into 2027-28, and approximately 10% EBITDA per share growth forecast. Barclays initiated coverage with an Overweight rating and a $59 price target, citing non-residential construction recovery, retrofit demand, and new product launches as key growth drivers.

Despite strong execution, the stock trades at a P/E ratio of 40.73 and InvestingPro analysis flags it as overvalued relative to its Fair Value, placing it on the Most Overvalued list. Seeking Alpha analysts have repeatedly questioned whether the growth profile justifies the premium multiple.

Barclays views Zurn Elkay as the most attractive way to play a recovery in non-residential construction within its water technology coverage. Limited municipal exposure and a meaningful retrofit demand base provide resilience, while incremental growth from new product launches and recurring filter replacement revenue further strengthen the outlook.

KeyBanc maintained only a Sector Weight rating despite the company's solid Q1 2026 performance, suggesting skepticism about the pace or durability of end-market recovery. The cautious stance implies that non-residential construction tailwinds may not translate into sustained above-market growth for ZWS.

Zurn Elkay raised its 2025 guidance to 5%+ core sales growth with a $420M–$430M EBITDA outlook, backed by impressive Q1 2026 results including 11% organic growth and EPS of $0.41 beating estimates by 14%. Stifel reaffirmed its Buy rating with a $59 target, highlighting the company's strong and consistent growth trajectory.

Seeking Alpha analysts have questioned whether Zurn Elkay's growth is actually accretive to shareholder value, with one analysis titled 'Growth Not Accretive To Shareholder Value' arguing that the company's expansion has not sufficiently rewarded shareholders. Another piece urged investors to 'Turn Off The Tap,' signaling deeper concerns about long-term returns.